Parabilis IPO Expansion
Parabilis, formerly FogPharma, increased its planned IPO size to as much as $636.8 million, potentially becoming one of the largest biotech IPOs in recent years. The financing represents a major validation event for the…
Technology Modalities
Regeneron – Gene Therapy Approved for Hearing Loss
Regeneron has received FDA approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy for genetic hearing loss caused by biallelic OTOF variants, marking a major milestone in sensory-organ gene therapy.
Cartherics – CAR-NK Manufacturing Expansion
Cartherics and Catalent have expanded their manufacturing partnership to support development and commercialization of iPSC-derived CAR-NK cell therapies. The agreement strengthens access to Catalent’s cGMP-compliant iPSC platform, supporting multiple programs including lead candidate CTH-401.What…
Life Biosciences – $80M Gene Therapy Financing
Life Biosciences has raised $80 million to support clinical development of its anti-aging gene therapy program, marking a notable financing event in the longevity and gene therapy space.What HappenedThe company secured $80M in financing…
Orca Bio – FDA Extends Orca-T Review Timeline
The FDA has extended the review timeline for Orca Bio’s biologics license application (BLA) for Orca-T, a high-precision allogeneic cell therapy for hematologic malignancies. The updated PDUFA date has been moved from April 6,…
Alltrna / tRNA Therapy – First Clinical Trial Approaching for Nonsense Mutation Diseases
The RNA therapeutics field is approaching a key inflection point with the anticipated initiation of the first clinical trial of engineered transfer RNA (tRNA) therapy, led by emerging players such as Alltrna. This modality…
Fortress Biotech, $205M Priority Review Voucher Sale
Fortress Biotech, through its subsidiary Cyprium Therapeutics, has completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million following the FDA approval of ZYCUBO (copper histidinate) for Menkes disease….
